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This study was performed to determine whether thromboxane A2
(as the analogue U46619) and serotonin can cause vasoconstriction
of moderately well developed coronary collateral vessels. Studies
were carried out in seven adult mongrel dogs 2 to 4 months after
embolic occlusion of the left anterior descending coronary artery
had been performed to stimulate collateral vessel growth. At the
time of study this artery was cannulated to determine interarterial
collateral flow from measurements of retrograde blood flow.
Radioactive microspheres were administered during retrograde
flow collection to determine continuing tissue flow for evaluation
of microvascular collateral communications.
Serotonin (50 Jtg!min) resulted in a 48 ± 11 % decrease in
retrograde flow (p < 0.01), with a 36 ± 10% decrease in total
The transformation of native intercoronary microvascular
anastomotic channels into mature collateral vessels in re-
sponse to coronary artery occlusoin has been well docu-
mented (1). These mature collateral vessels have structural
characteristics that are similar to small arteries and are
capable of vasomotor activity (1-3). However, the responses
of collateral vessels to vasoactive stimuli may differ from the
responses of other segments of the coronary artery vascula-
ture. For example, although both epicardial arteries and
collateral vessels undergo vasodilation in response to nitro-
glycerin and atrial natriuretic peptide (3-5), epicardial arter-
ies but not collateral vessels constrict in response to alpha-
adrenergic agonists (6-8), and epicardial arteries dilate,
whereas collateral vessels constrict in response to vasopres-
sin (7-9). Thus, knowledge of the action of vasoactive
substances on large coronary arteries or on coronary resis-
tance vessels cannot be generalized to the coronary collat-
eral circulation. The platelet products serotonin and throm-
boxane A2 cause constriction of epicardial coronary arteries,
but the effects of these agents on coronary collateral blood
flow have not been reported (10-12).
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collateral blood flow (p < 0.02). Infusion of U46619 (0.01 pg/kg
per min) caused a 38 ± 13% decrease in retrograde blood flow
(p < 0.01), with a 34 ± 13% decrease in total collateral flow (p <
0.05). Serotonin caused a significant increase in tissue flow to the
subepicardium of the collateral-dependent region, whereas
U46619 caused no change in tissue blood flow.
These data demonstrate that both serotonin and thromboxane
A2 can cause vasoconstriction of interarterial coronary collateral
vessels. The findings suggest that platelet activation in coronary
arteries from which collateral vessels originate has potential for
causing collateral vasoconstriction, thereby compromising blood
flow to the dependent myocardium.
(J Am Coll CardioI1992;19:687-93)
Consequently, the present study was performed to deter-
mine whether thromboxane A2 (as the analogue U46619) and
serotonin cause vasoconstriction of moderately well devel-
oped coronary collateral vessels. Studies were carried out in
dogs in which collateral vessel growth had been stimulated
by placement of a gradually occluding intravascular plug into
a coronary artery 2 to 4 months before study. Retrograde
flow from the cannulated collateralized artery was used to
assess interarterial collateral vasculature; continuing tissue
flow was measured with microspheres to assess microvas-
cular collateral communications (13).
Methods
Induction of collateral vessels. These studies were carried
out in accordance with the "Position of the American Heart
Association on Research Animal Use" adopted November
11, 1984 and under the supervision of the Animal Care
Committee of the University of Minnesota. Coronary collat-
eral vessel growth was stimulated by placement of an
intravascular plug into the left anterior descending coronary
artery. Seven adult mongrel dogs weighing 20 to 30 kg were
premedicated with atenolol (50 mg orally), aspirin (325 mg)
and morphine sulfate (1 mg/kg body weight subcutaneously)
1h before induction of anesthesia with sodium thiamylal (20
to 30 mg/kg intravenously). The dogs were intubated and
ventilated with a respirator using room air supplemented
with oxygen. A right carotid arteriotomy was performed
under sterile surgical conditions. After administration of
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heparin sodium (200 U/kg intravenously) and lidocaine
(2 mg/kg intravenously), a 7F Judkins JR4 coronary catheter
was introduced into the right carotid artery and advanced to
the ostium of the left main coronary artery under fluoro-
scopic guidance. A 0.014 in. (0.036 cm) angioplasty guide
wire was inserted into the coronary catheter, guided into the
anterior descending coronary artery and advanced to the
cardiac apex. The catheter was withdrawn and a hollow
stainless steel plug (3 mm length x 2.3 to 3 mm outer
diameter; 1.1 mm inner diameter) was advanced over the
guide wire until it was firmly wedged in the mid-portion of
the anterior descending artery. The guide wire was then
removed and radiopaque contrast material was administered
to confirm the position of the plug. The arteriotomy was
repaired and the animal allowed to recover.
Surgical preparation. Studies were performed 2to 4months
after placement of the intravascular plug. The dogs were
premedicated with morphine sulfate (1.2 mg/kg subcutaneous-
ly), anesthetized with alpha-chloralose (100 mg/kg intravenous-
ly), intubated and ventilated with room air supplemented with
oxygen. A 7F National Institutes of Health catheter was
introduced into the right femoral artery and advanced into the
left ventricle for pressure measurement. A similar catheter was
introduced into the left femoral artery and advanced into the
left ventricle for pressure measurement. A similar catheter was
introduced into the left femoral artery and advanced into the
ascending aorta. A thoracotomy was performed in the left
fourth intercostal space. Apneumatic cuffoccluder was placed
around the descending thoracic aorta for control of aortic
pressure. The heart was suspended in a pericardial cradle and
a PVC catheter (3 mm outer diameter) was inserted into the left
atrium through the atrial appendage. The intravascular plug
was located in the coronary artery by palpation, and the artery
was mobilized in this region. A PESO catheter was introduced
proximal to the plug in a retrograde direction and positioned
with the catheter tip in the left main coronary artery for
drug infusion. Heparin sodium (200 U/kg intravenously fol-
lowed by 1,000 U/h) was administered, and the coronary artery
plug was removed through an arteriotomy, allowing free retro-
grade flow of blood to displace any residual thrombus. The
artery was then cannulated with a thin wall stainless steel
cannula (4 mm outer diameter) in which 23-gauge tubing had
been incorporated to monitor pressure at the cannula tip.
Myocardial blood flow measurement. Regional myocar-
dial blood flow was measured using IS-pm diameter micro-
spheres labeled with iodine-125, niobium-95, strontium-85,
chromium-51, scandium-46 or cerium-141 (3M Company and
New England Nuclear). Microspheres were obtained as
1 mCi in 10 ml of 10% low molecular weight dextran and
agitated in an ultrasonic bath for at least 15 min before
injection. For each intervention, 3 x 106 microspheres were
injected into the left atrium; a reference sample of arterial
blood was withdrawn from the aortic catheter at a constant
rate of 15 mUmin with a peristaltic pump (Harvard model
551). Reference blood sampling was begun at the time of
microsphere injection and continued for 90 s.
Experimental protocol. Left ventricular, aortic and coro-
nary cannula pressures were monitored with use of Spec-
tramed TNF-R pressure transducers. Left ventricular pres-
sure was displayed at normal and high gain for measurement
of end-diastolic pressure. Data were recorded on a Hewlett-
Packard 8800 eight-channel direct-writing oscillograph. In-
terarterial collateral blood flow measurements were per-
formed by collecting retrograde flow from the coronary
cannula into a graduated cylinder over 30 s while the cannula
tip was maintained at the level of the heart. Control retro-
grade flow collections were repeated until consistent mea-
surements were obtained. Retrograde pressure measure-
ments were monitored continuously. An initial injection of
microsphere injection was then performed with the cannula
open to air to assess the degree of continuing tissue flow
while the retrograde flow collection was performed.
Serotonin. After control measurements were completed,
the response to serotonin was examined. A low dose of
serotonin (10 JLg/min) was infused at a constant rate
(0.49 ml/min) into the left main coronary artery catheter for
10 min with a syringe pump (Harvard Instruments model
701). Retrograde blood flow measurements were obtained at
2, 4 and 8 min of drug infusion. The serotonin dose was then
increased to 50 JLg/min by increasing the concentration of
serotonin with no change in infusion rate. Retrograde flow
measurements were again obtained at 2, 4 and 8 min of drug
infusion. A third injection of microspheres was performed
simultaneously with the 8-min retrograde flow collection.
The serotonin infusion was then discontinued and the dog
allowed to recover for 30 min.
Thromboxane A2• Hemodynamic measurements and ret-
rograde flow collections were repeated to confirm return to
baseline levels. The effect of thromboxane Az was then
assessed by infusion of U46619 into the left main coronary
artery catheter at a dose of 0.001 }log/kg per min and an
infusion rate of0.49 mUmin. Retrograde flows were collected
at 2, 4 and 8 min. The dose was then increased to 0.01 J,tg/kg
per min; retrograde flow measurements were repeated at 2, 4
and 8 min, and a microsphere injection was performed
simultaneously with the 8-min collection.
Identification of collateral-dependent myocardium. After
completion of study, the shadow technique of Patterson and
Kirk (14) was used to delineate the perfusion bed of the
cannulated left anterior descending coronary artery. The
coronary cannula was perfused with nonradioactive arterial
blood previously collected from the dog in a pressurized
reservoir. Cannula tip pressure was maintained 5 to
10 mm Hg above mean aortic pressure during the micro-
sphere injection. In this way, the area of left ventricle
perfused by the anterior descending artery distal to the site
of occlusion was marked with nonradioactive blood to
distinguish it from the remainder of the heart, which was
perfused from the aorta with microsphere-containing blood.
Tissue preparation. At the conclusion of the study, the
animal was killed and the heart excised and fixed in 10%
buffered formalin. The left ventricle was sectioned into five
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transverse rings from base to apex, In four dogs a thin rim of
subendocardial scar was found in the collateral-dependent
region. This healed infarct, which accounted for <5% of the
weight of the collateral region, was removed before the
tissue was prepared for counting. Each ring was sectioned
radially into 16 segments, which were then subdivided into
epicardial and endocardial valves, weighed on an analytical
balance and placed into vials for counting. Myocardial and
blood reference specimens were counted in a Packard model
5912 gamma counter at window settings corresponding to the
peak energies of each radionuclide. The activity in each
energy window was corrected for background and for over-
lapping counts between isotopes with a digital computer.
Blood flow to each myocardial specimen (Qm) was com-
puted with the formula: Qm == Qr x Cm/Cr, where Qr ==
reference blood flow rate (ml/min), Cm == counts/min of the
myocardial specimen and Cr == counts/min of the reference
blood specimen. Blood flows were expressed as ml/min per
g of myocardium. To obtain total myocardial tissue flow to
the collateral-dependent myocardium, absolute blood flows
were summed for all specimens identified by the shadow
technique to represent myocardium perfused by the left
anterior descending coronary artery. Duplicate specimens
from the posterior wall were used to assess blood flow from
normally perfused myocardium.
Data analysis. Hemodynamic data were measured di-
rectly from the strip chart recordings. Hemodynamic varia-
bles and retrograde blood flow during control conditions and
with each intervention were compared by using analysis of
variance for repeated measures. A value of p < 0.05 was
required for statistical significance. When a significant dif-
ference was found, individual comparisons were made with
the Scheffe method. Tissue flow measurements made with
microspheres were compared with use of the Wilcoxon
signed-rank test. All data are expressed as mean values ±
SEM.
Results
Hemodynamic data. Hemodynamic measurements ob-
tained during control conditions, and during infusion of two
doses of serotonin and two doses of U46619 are shown in
Table 1. Heart rate and left ventricular end-diastolic pres-
sures were not significantly different between the control
period and either drug intervention. Mean aortic pressure
was slightly but significantly increased by both doses of
U46619 and left ventricular systolic pressure was increased
during high dose U46619. A trend toward decreased mean
aortic pressure with serotonin (50 JLg/min) did not achieve
statistical significance.
Retrograde blood flow. Retrograde flow collections from
the left anterior descending coronary artery cannula are
shown in Table 2. During control conditions before infusion
of serotonin, mean retrograde blood flow was 36.4 ±
12 ml/min (range 10 to 101 ml/min). Serotonin in a dose of
10 JLg/min caused a 27 ± 7% decrease in retrograde blood
Table 1. Hemodynamic Data From Seven Dogs During Control
Conditions and During Infusions of Serotonin and U46619
Pressures (mm Hg)
Heart Rate Mean LV LV End-
(beats/min) Aortic Systolic Diastolic
Control serotonin 130 ± 5 98 ± 7 114 ± 8 9 ± 2
10 iLg/min 126 ± 7 94 ± 2 113 ± 4 9 ± 2
50 iLg/min 126 ± 6 89 ± 6 109 ± 5 6 ± 1
Control U46619 123 ± 7 98 ± 5 119 ± 5 8 ± 1
0.001 iLg/kg per min 125 ± 6 103 ± 4' 124 ± 7 8 ± 1
0.01 iLg/kg per min 122 ± 7 106 ± 5' 130 ± 8' 9 ± 1
'p < 0.05 versus control value. Values are mean values ± SEM. LV = left
ventricular.
flow (p < 0.05). This decrease was similar at 2, 4 and 8 min
of serotonin infusion. Increasing the serotonin infusion rate
to 50 JLg/min significantly further decreased the retrograde
flow to 48 ± 11% below the control value (range - 5 to
-80%; p < 0.01). The decrease in retrograde flow was
similar at 2, 4 and 8 min of infusion (Fig. 1).
During baseline conditions before administration of
U46619 mean retrograde blood flow was 32.2 ± 12.1 ml/min
(range 10 to 88) (Table 2). There was no significant change in
retrograde blood flow during infusion of U46619 at a dose of
0.001 JLg/kg per min. However, retrograde flow decreased
significantly during infusion of U46619 at a dose of
0.01 JLg/kg per min, with a decrease of 38 ± 13% after 8 min
of infusion of U46619 (range 0 to -80%; p < 0.05). The
decrease in retrograde flow produced by U46619 was not
seen until 4 min after the start of infusion, and then remained
stable between 4 and 8 min of drug infusion (Fig. 2).
Collateral zone. The shadow technique demonstrated
sharp boundaries between collateral-dependent and normal
zones. Total mass of the collateral-dependent region ranged
from 2.42 to 29.6 g (mean 16 ± 4.3). The size of the
collateral-dependent region corresponded to the distance
along the coronary artery at which the intravascular plug
was positioned. Total left ventricular mass was 103.4 ±
5.6 g; collateral-dependent tissue represented 15.3 ± 4.3% of
the left ventricle.
Tissue blood ftow. Myocardial tissue flow measured with
microspheres is shown in Table 3. During control conditions
with the coronary cannula closed, there was no significant
difference in blood flow to normally perfused and collateral-
dependent myocardium. On opening the coronary cannula,
mean myocardial tissue flow decreased to 55 ± 16% of
normal zone flow (p < 0.01). The responses of tissue blood
flow during administration of serotonin and U46619 were
measured with the coronary cannula open, indicating micro-
vascular flow not diverted during the retrograde flow collec-
tion. In the normal zone serotonin caused a 123 ± 19%
increase in mean tissue flow with significant increases in flow
to both subendocardial and subepicardial muscle (p < 0.01).
Serotonin infusion increased blood flow to the subepicar-
dium of the collateral-dependent region (p < 0.05), but did
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Table 2. Retrograde Blood Flow, Flow to the Collateral-Dependent Myocardium Measured With Microspheres, Total Collateral Flow and
Collateral Vascular Resistance During Control Conditions and During Infusion of Serotonin and U46619 in Seven Dogs
Total Collateral Blood Flow
(A + B)A. Retrograde
Blood Flow
(mVmin)
B. Collateral-Dependent
Tissue Blood Flow
(mVmin) ml/min ml/min per 100 g
Mean Arterial
Pressure
(mm Hg)
Collateral Vascular
Resistance
(mm Hg . min . 100 glml)
Serotonin study
Control 36.4 ± 12
Serotonin 24.6 ± 12.9*
(50 ~min)
U46619 study
Control 32.2 ± 12.1
U46619 26.3 ± 13.4*
(0.01 ~kg per min)
11.9 ± 4.6
13 ± 5.6
13.6 ± 5.1
10.6 ± 4.5
48.4 ± 14.9
37.6 ± 16.2*
45.8 ± 14.7
36.9 ± 17.3*
413 ± 86
288 ± 91*
339 ± 87
256 ± 101*
98 ± 7
89 ± 6
98 ± 5
106 ± 5*
24.2 ± 9
33.4 ± 12*
28.9 ± 8
41.4 ± 15.9*
Values are mean values ± SEM. *p < 0.05 in comparison with control conditions.
not significantly alter blood flow to the subendocardium.
U46619 did not cause a significant change in normal zone
flow. Although collateral zone tissue flow tended to decrease
during infusion of U46619, the reduction did not achieve
statistical significance.
Total collateral ftow. Total collateral blood flow (the sum
of retrograde flow plus tissue flow in the collateral-
dependent region) and collateral vascular resistance, ex-
pressed per g of collateral-dependent myocardium, are
shown in Table 2. Infusion of serotonin (50 JLg/min) caused a
36 ± 10% decrease in total collateral blood flow (p < 0.02),
with a 54 ± 22% increase in collateral vascular resistance
(p < 0.05). Infusion of U46619 (0.01 JLg/min) caused a 34 ±
13% decrease in total collateral blood flow (p < 0.05), with a
proportionate increase in collateral vascular resistance (p <
0.01).
Discussion
Previous studies have demonstrated that thromboxane Az
and serotonin cause constriction of large coronary arteries
(10-12). The present study demonstrates that these platelet-
derived mediators also cause constriction of well developed
coronary collateral vessels. The methodology used to mea-
sure collateral blood flow and the potential significance of
these experimental findings will be discussed in detail.
Methodologic considerations. Collateral blood flow was
determined as the sum of retrograde flow from the cannu-
lated coronary artery and continuing tissue flow in the
collateral-dependent myocardium. This procedure was fol-
lowed because Downey et al. (13) have documented the
development of two separate components of collateral vas-
culature in response to coronary artery occlusion. Blood
diverted into the coronary artery cannula is derived from
interarterial collateral vessels that are principally epicardial
in location (13). This interarterial component represented
approximately 75% of total collateral flow and was respon-
sible for most of the change in collateral flow in response to
the vasoactive agents used in our study. Continuing tissue
flow measured with microspheres during retrograde flow
diversion represents blood delivered into the recipient vas-
cular system through microvascular communications that
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Table 3. Myocardial Tissue Flow Measured With Microspheres in Seven Dogs During Control Conditions and During
Infusion of Serotonin
Blood Flow (ml/min per g)
Subendocardial Subepicardial Mean Myocardial
Normal Collateral Normal Collateral Normal Collateral
Control
Cannula closed 1.26 :!: 0.37 1.08 :!: 0.18 1.46 :!: 0.23 1.29 :!: 0.24 1.33 :!: 0.19 1.20 :!: 0.21
Cannula open 1.08 :!: 0.18 0.56:!: 0.17 0.99:!: 0.13 0.73 :!: 0.17 1.03 :!: 0.95 0.66:!: 1.48
Serotonin
(50 p.g/min) 2.1 :!: 0.36* 0.62 :!: 0.11 2.51 :!: 0.42* 1.10 :!: 0.22* 2.33 :!: 0.38* 0.89 :!: 0.16
U46619
(0.01 /Lg/kg per min) 1.23 :!: 0.19 0.42 :!: 0.15 1.28 :!: 0.1 0.63 :!: 0.16 1.25 :!: 0.85 0.54 :!: 1.96
*p < 0.05 in comparison with the respective measurement during control conditions with the cannula open. Collateral = collateral-dependent myocardium;
Normal = normally perfused.
are intramural in location (13). Both retrograde flow and
tissue flow into the occluded vascular bed were measured in
the present study, thereby accounting for total collateral
blood flow.
Vasoactive agents were infused into the left main coro-
nary artery. They were therefore delivered to collateral
vessels arising from the left circumflex, septal and anterior
descending artery proximal to the site of obstruction, but not
to collateral vessels originating from the right coronary
artery. Failure of vasoactive agents to reach collateral ves-
sels from the right coronary artery would cause underesti-
mation of the effect of these agents. However, Scheel et al.
(5) demonstrated that in the canine heart only approxi-
mately 10% of collateral flow into the anterior descending
artery arises from the right coronary artery. This relatively
small contribution to collateral blood flow from the right
coronary artery should have caused only slight underestima-
tion of the effects of the agents tested on collateral flow.
The present study was performed in anesthetized dogs
with surgically placed instruments. General anesthesia and
surgical preparation cause neuroendocrine activation that
increases the basal level of vasoconstriction in the coronary
system (6). The presence of increased coronary vasocon-
strictor tone would impair the ability for further constriction
in response to the agents tested. For this reason, the
responses observed in the present study may underestimate
the responses that would occur in an intact awake animal.
Serotonin. Although serotonin does not normally circu-
late in sufficient concentrations to cause coronary vasomotor
activity, its release by aggregating platelets may result in
local blood concentrations that reach the micromolar range
(7). In the normal coronary artery circulation serotonin
exerts differing effects depending on vessel size (8). Mea-
surements obtained with quantitative angiography or with
ultrasonic microcrystals have demonstrated 00-12) that the
large epicardial coronary arteries undergo vasoconstriction
in response to serotonin. Similarly, studies (9) of coronary
artery ring preparations have shown vasoconstriction in
response to serotonin. In contrast to the epicardial coronary
artery vasoconstriction, intraarterial administration of sero-
tonin has resulted in increased coronary blood flow, indicat-
ing vasodilation of the coronary resistance vessels
00,12,18). In agreement with this finding, in the present
study serotonin caused a 226% increase in mean blood flow
to the normally perfused area.
No previous data are available on the effects of serotonin
on collateral blood flow in vivo. Akita et al. (20) examined
the effect of serotonin on isolated helical strips of epicardial
coronary collateral vessels and normal epicardial arteries
from dogs 2 to 4 months after placement of an ameroid
constrictor on the left circumflex coronary artery. Serotonin
produced contraction of both epicardial artery strips and
collateral vessel strips with a threshold dose of 10- 10 M. The
present study extends these previous in vitro findings by
demonstrating that serotonin also caused a decrease in
retrograde blood flow in the intact animal. This finding is
consonant with the concept that serotonin causes vasocon-
striction of epicardial coronary collateral vessels. However,
serotonin had an opposite effect on microvascular collateral
blood flow, causing an increase in subepicardial tissue flow
in the collateralized region. This finding may be interpreted
in light of the report of Lamping et al. (8) that in normal
hearts serotonin caused constriction of coronary artery
vessels >90 /Lm in diameter, but dilation of arterioles
<90 /Lm in diameter. Epicardial interarterial collateral ves-
sels that develop in response to chronic coronary occlusion
are generally larger than 200 /Lm in diameter, whereas
intramural interarteriolar communications are generally
smaller than 80 /Lm in diameter 03,21). The present findings
indicate that in the coronary collateral circulation, as among
other coronary artery vessels, larger vessels undergo vaso-
constriction in response to serotonin, whereas the smaller
interarteriolar communications undergo vasodilation.
Thromboxane A2• Thromboxane Az is a product of pros-
taglandin endoperoxide metabolism liberated during platelet
aggregation (22). Because thromboxane Az has a half-life of
only 30 s, the stable thromboxane Az mimetic U46619 was
used in the present study (23,24). Thromboxane Az or its
analogues have been shown to produce vasoconstriction of
both epicardial coronary arteries and coronary resistance
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vessels (22,24). The present data provide the first evidence
that thromboxane Az also constricts coronary collateral
vessels. U46619 decreased retrograde flow but did not de-
crease continuing tissue blood flow to the collateral-
dependent region, indicating that thromboxane Az causes
constriction of the interarterial collateral vessels, which are
principally epicardial in location, but does not cause con-
striction of the small intramural collateral vessels. U46619
caused a significant decrease in retrograde blood flow at a
dose that did not alter tissue flow in either the normally
perfused or collateral-dependent region, suggesting that the
interarterial collateral vessels are more sensitive to the
vasoconstrictor effects of thromboxane than are the coro-
nary resistance vessels. Mehta et al. (25) reported that
U46619 administered intravenously to normal dogs, in larger
dogs than those used in the present study, caused vasocon-
striction of the coronary resistance vessels which was fol-
lowed by vasodilation. The delayed vasodilation phase was
mediated by endogenous prostacyclin (PGIz) and could be
blocked with cyclooxygenase inhibitors. In contrast, U46619
did not cause vasodilation in either the normally perfused or
the collateral·dependent myocardial regions in our study.
This difference may be related to the larger doses or the
intravenous route of administration used by Mehta et al.
(25), or to the use of bolus injections rather than a continu-
ous infusion. In a recent study, Ruocco et al. (26) found that
intraarterial infusion of U46619 in swine produced vasocon-
striction of coronary resistance vessels that decreased blood
flow even in the presence of an arterial stenosis.
Blood concentrations. It is important to consider whether
the doses of vasoactive agents resulted in blood concentra-
tions that could be achieved in patients with coronary artery
disease. Because tissue flows to normally perfused and
collateral-dependent myocardial regions and retrograde flow
were directly measured, it is possible to calculate total blood
flow through the left main coronary artery into which the
drug was diluted. On the basis of these measurements
infusion of serotonin at a dose of 10 ILg/min resulted in a
computed coronary blood concentration of approximately
6 x 10-6 M. In a previous study (27) of coronary artery
thrombus formation in a canine model, serotonin concentra-
tions were reported to reach levels of 2 x 10-6 M, whereas
in vitro studies (17) have shown that serotonin released by
aggregating platelets in numbers found in circulating blood
can result in local concentrations as high as 6 x 10-4 M.
Thus, concentrations of serotonin similar to those used in
the present study could be achieved during platelet aggrega-
tion in vivo. The calculated coronary artery blood concen-
tration during infusion of U46619 at a dose of O.OllLg/kg per
min was 6 x 10-9 M. Although direct measurements of
thromboxane Az concentrations in coronary artery blood in
vivo are not available, the concentration that caused collat-
eral vasoconstriction in the present study is less than that
which produces maximal coronary artery vasoconstriction in
vitro (24).
Clinical implications. Unstable myocardial ischemic syn-
dromes are frequently associated with evidence for intravas-
cular platelet activation (28-30). In addition to causing
worsening of stenosis severity by increasing the degree of
mechanical obstruction at the site of an atherosclerotic
lesion, activated platelets liberate vasoactive substances,
including serotonin and thromboxane Az, which may cause
vasoconstriction of epicardial arteries and coronary resis-
tance vessels (31). In patients with multivessel coronary
artery disease, collateral vessels may originate distal to an
atherosclerotic lesion. Platelet activation occurring at the
site of such a lesion would result in liberation of serotonin
and thromboxane Az, which could cause constriction not
only of the epicardial artery segment and resistance vessels
in the dependent vasculature, but also of collateral vessels
originating distal to the stenosis. Vasoconstriction of collat-
eral vessels in response to serotonin or thromboxane Az
could further jeopardize perfusion of the collateral-
dependent myocardium. In autopsy studies of patients who
died with an acute myocardial ischemic syndrome, Blumgart
et al. (32) described the occurrence of "infarction at a
distance." In these patients the area of infarct was not the
region directly perfused by a stenotic coronary artery, but
rather a distant myocardial region that had been dependent
on the stenosed artery for perfusion through collateral ves-
sels. Although worsening stenosis severity resulting from
thrombus formation at the site of a coronary atheroma could
have jeopardized perfusion of the collateral-dependent myo-
cardium, collateral vessel constriction produced by products
of platelet activation could have also contributed to under-
perfusion of the dependent myocardium.
We acknowledge the expert technical assistance provided by Todd Pavik,
Melanie Crampton and Paul Lindstrom.
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